Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma

Diagnostic and Interventional Radiology

Volumn 20, Issue 2, 2014, Pages 185-192

  Ömür, Özgür ^a   Baran, Yusuf ^b   Oral, Aylin ^a   Ceylan, Yeşim ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; CONTRAST MEDIUM; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BONE; BONE MARROW; BONE MARROW BIOPSY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PREVALENCE; PROSTATE; RETROSPECTIVE STUDY; SPLEEN; THYROID GLAND; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84895437637     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2013.13174     Document Type: Article

References (26)

1. Chua SC, Rozalli FI, O'Connor SR. Imaging features of primary extranodal lymphomas. Clin Radiol 2009; 64:574-588. [CrossRef]
2. Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkin's disease. Radiol Clin North Am 2007; 45:697-709. [CrossRef]
3. Pates FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 2010; 30:269-291. [CrossRef]
4. Guermazzi A, Brice P, Kerviler E, et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics 2001; 21:161-179. [CrossRef]
5. Zucca E, Conconi A, Cavalli F. Treatment of extranodal lymphomas. Best Pract Res Clin Haematol 2002; 15:533-547. [CrossRef]
6. Ping L. Staging and classification of lymphoma. Semin Nucl Med 2005; 35:160-164. [CrossRef]
7. Schaefer NG, Hany TF, Tverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging do we need contrast-enhanced CT? Radiology 2004; 232:823-829. [CrossRef]
8. Leite NP, Kased N, Hanna RF, et al. Cross-sectional imaging of extranodal involvement in abdomino-pelvic lymphoproliferative malignancies. Radiographics 2007; 27:1613-1634. [CrossRef]
9. Seam P, Juweid ME, Chenson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507-3516. [CrossRef]
10. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology 2006; 2006:259-265. [CrossRef]
11. Juweid ME. FDG-PET/CT in lymphoma. Methods Mol Biol 2011; 727:1-19. [CrossRef]
12. Schaefer NG, Tverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed? Radiology 2007; 244:257-262. [CrossRef]
13. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206:475-481.
14. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25:721-728. [CrossRef]
15. Pakos EE, Fotopoulos AD, Ioannidis JPA. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46:958-963.
16. Wu L, Chenb F, Jiangc X, Gua H, Yina Y, Xua J. 18F-FDG PET, combined FDG-PET/ CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol 2012; 81:303-311. [CrossRef]
17. Rini JN, Leonidas JC, Tomas MB, Palestro CJ. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003; 44:1072-1074.
18. de Jong PA, van Ufford HM, Baarslag HJ, et al. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. Am J Roentgenol 2009; 192:745-753. [CrossRef]
19. Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging 2008; 35:1424-1430. [CrossRef]
20. Ili{dotless}ca AT, Kocaçelebi K, Savafl R, Ayan A. Imaging of extranodal lymphoma with PET/CT. Clin Nucl Med 2011; 36:127-138. [CrossRef]
21. Lee WK, Lau EWF, Duddalwar VA, Stanley AJ, Ho YY. Abdominal manifestations of extranodal lymphoma: spectrum of imaging findings. Am J Roentgenol 2008; 191:198-206. [CrossRef]
22. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30:117-127. [CrossRef]
23. Tan LHC. Lymphomas involving Waldeyer's ring: placement, paradigms, peculiarities, pitfalls, patterns and postulates. Ann Acad Med Singapore 2004; 33:15S-26S.
24. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. Am J Roentgenol 2010; 195:310-320. [CrossRef]
25. Benz MR, Evilevitch V, Allen-Auerbach MS, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 2008; 49:1038-1046. [CrossRef]
26. Oh MY, Oh SB, Seoung HG, et al. Clinical significance of standardized uptake value and maximum tumor diameter in patients with primary extranodal diffuse large B cell lymphoma. Korean J Hematol 2012; 47:207-212. [CrossRef]